|Slideshows|March 30, 2018

Psychiatry Update: March 2018

Author(s)Natalie Timoshin, Laurie Martin

News from around the web includes reports on physician burnout, the effects of diet on brain inflammation, written exposure therapy for PTSD, Parkland, psychedelics, benzodiazepines, and social media to gauge mental health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Psyched Perspectives: Culturally Responsive Psychiatry, Insights From APA Fellow Diego Regalado, MD

ByFrank A. Clark, MD,Diego Regalado, MD

July 28th 2026

The Wind Check: How to Adapt Recovery and Shared Decision-Making Across Cultures

ByYasuhiro Kotera, PhD

July 22nd 2026

Psyched Perspectives: Building Community in Psychiatric Practice, Reflections From Lindsay Hill, DNP, PMHNP

ByFrank A. Clark, MD,Lindsay Hill, DNP, PMHNP

May 1st 2026

Why Are Assisted Suicide and Euthanasia Not Accepted in Eastern Cultures?

ByRonald W. Pies, MD,Cynthia M.A. Geppert, MD, PhD, MA, MPH, MSBE, DPS, MSJ,Mark S. Komrad, MD, DFAPA

April 3rd 2026

Culture as Wind: Adapting Recovery and Shared Decision-Making Across Cultures

ByYasuhiro Kotera, PhD

March 25th 2026

Latest CME

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Psychiatry Update: March 2018

Related Content

Psyched Perspectives: Culturally Responsive Psychiatry, Insights From APA Fellow Diego Regalado, MD

The Wind Check: How to Adapt Recovery and Shared Decision-Making Across Cultures

Psyched Perspectives: Building Community in Psychiatric Practice, Reflections From Lindsay Hill, DNP, PMHNP

Why Are Assisted Suicide and Euthanasia Not Accepted in Eastern Cultures?

Culture as Wind: Adapting Recovery and Shared Decision-Making Across Cultures

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD